108 related articles for article (PubMed ID: 9585806)
1. Alpha interferon treatment in myasthenia gravis: effects on natural killer cell activity.
Bolay H; Karabudak R; Aybay C; Candemir H; Varli K; Imir T; Kansu E
J Neuroimmunol; 1998 Mar; 82(2):109-15. PubMed ID: 9585806
[TBL] [Abstract][Full Text] [Related]
2. Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C.
Appasamy R; Bryant J; Hassanein T; Van Thiel DH; Whiteside TL
Clin Immunol Immunopathol; 1994 Dec; 73(3):350-7. PubMed ID: 7955564
[TBL] [Abstract][Full Text] [Related]
3. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
4. The T-cell repertoire in myasthenia gravis involves multiple cholinergic receptor epitopes.
Link H; Xu ZY; Melms A; Kalbacher H; Sun JB; Wang ZY; Fredrikson S; Olsson T
Scand J Immunol; 1992 Sep; 36(3):405-14. PubMed ID: 1381518
[TBL] [Abstract][Full Text] [Related]
5. Effects of maximal exercise on natural killer (NK) cell cytotoxicity and responsiveness to interferon-alpha in the young and old.
Woods JA; Evans JK; Wolters BW; Ceddia MA; McAuley E
J Gerontol A Biol Sci Med Sci; 1998 Nov; 53(6):B430-7. PubMed ID: 9823739
[TBL] [Abstract][Full Text] [Related]
6. IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis.
Shenoy M; Baron S; Wu B; Goluszko E; Christadoss P
J Immunol; 1995 Jun; 154(11):6203-8. PubMed ID: 7751658
[TBL] [Abstract][Full Text] [Related]
7. Altered populations of natural killer cell and natural killer T cell subclasses in myasthenia gravis.
Suzuki Y; Onodera H; Tago H; Saito R; Ohuchi M; Shimizu M; Itoyama Y
J Neuroimmunol; 2005 Oct; 167(1-2):186-9. PubMed ID: 16040133
[TBL] [Abstract][Full Text] [Related]
8. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
9. Effect of alpha-interferon on natural killer cell activity and lymphocyte subsets in thalassemia patients with chronic hepatitis C.
Malaponte G; Passero E; Leonardi S; Monte V; Lauria C; Mazzarino C; Sciotto A; Russo Mancuso G; Di Gregorio F; Musumeci S
Acta Haematol; 1997; 98(2):83-8. PubMed ID: 9286304
[TBL] [Abstract][Full Text] [Related]
10. Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection.
Pár G; Rukavina D; Podack ER; Horányi M; Szekeres-Barthó J; Hegedüs G; Paál M; Szereday L; Mózsik G; Pár A
J Hepatol; 2002 Oct; 37(4):514-22. PubMed ID: 12217606
[TBL] [Abstract][Full Text] [Related]
11. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
12. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis.
Chien PJ; Yeh JH; Chiu HC; Hsueh YM; Chen CT; Chen MC; Shih CM
Eur J Neurol; 2011 Nov; 18(11):1350-7. PubMed ID: 21554496
[TBL] [Abstract][Full Text] [Related]
14. Persistence of CD16+/CD56-/2B4+ natural killer cells: a highly dysfunctional NK subset expanded in ocular myasthenia gravis.
Nguyen S; Morel V; Le Garff-Tavernier M; Bolgert F; Leblond V; Debré P; Vieillard V
J Neuroimmunol; 2006 Oct; 179(1-2):117-25. PubMed ID: 16904757
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.
Millar BC; Bell JB; Powles RL
Br J Cancer; 1996 Jan; 73(2):236-40. PubMed ID: 8546912
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
[TBL] [Abstract][Full Text] [Related]
17. Production of anti-acetylcholine receptor-alpha antibody in vitro by peripheral blood lymphocytes of patients with myasthenia gravis: role of immunoregulatory T cells and monocytes.
Ofosu-Appiah W; Mokhtarian F; Shirazian D; Grob D
J Lab Clin Med; 1994 Aug; 124(2):231-41. PubMed ID: 8051487
[TBL] [Abstract][Full Text] [Related]
18. Recombinant alpha-2b-interferon may restore natural-killer activity in patients with B-chronic lymphocytic leukemia.
Villamor N; Reverter JC; Montserrat E; Urbano-Ispízua A; Vives-Corrons JL; Rozman C
Leukemia; 1992 Jun; 6(6):547-52. PubMed ID: 1376376
[TBL] [Abstract][Full Text] [Related]
19. The effects of general anesthesia and surgery on basal and interferon stimulated natural killer cell activity of humans.
Kutza J; Gratz I; Afshar M; Murasko DM
Anesth Analg; 1997 Oct; 85(4):918-23. PubMed ID: 9322480
[TBL] [Abstract][Full Text] [Related]
20. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.
Schiller JH; Hank J; Storer B; Borchert AA; Moore KH; Albertini M; Bechhofer R; Wesley O; Brown RR; Bastin AM
Cancer Res; 1993 Mar; 53(6):1286-92. PubMed ID: 8443808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
